You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥科技股份(08156.HK):永衍控股建議以發行股本方式籌集400萬港元
格隆匯 06-07 22:44

格隆匯6月7日丨國藥科技股份(08156.HK)公吿,於2022年5月31日,公司全資附屬公司國藥科技企業管理有限公司收到一份由公司的聯營公司永衍控股有限公司(要約人)發出的要約函,邀請要約人各股東認購新股。

於本公吿日期,要約人由國科企管擁有40%及由獨立於公司及其關連人士的第三方擁有60%。根據要約函,要約人及其附屬公司面臨財務困難,而要約人集團將需要至少400萬港元的營運資金。監於資金短缺,要約人建議要約人以發行股本的方式籌集400萬港元,而要約人的所有股東(包括國科企管)將有權按其在要約人的現有股權比例認購其各自的新股份,並且任何未被要約人任何股東認購的新股份將由要約人的其他自願股東以相同的認購價每股新股4,000港元認購。

根據集資方案,國科企管有權選擇(a)認購總額最多160萬港元的新股,以維持其於要約人的股權比例;或(b)同意集資方案,但決定不向要約人認購新股;或(c)不批准籌資建議。倘國科企管選擇不參與籌資建議,其於要約人的股權可能被攤薄至約20%。

要約人為投資控股公司,持有健福堂中醫集團有限公司100%股權,其主要在香港從事現代化中醫診所業務。國科企管於2022年6月6日回覆要約人,國科企管同意集資方案,但不會認購新股以參與集資方案。經慎重考慮後,董事認為要約人集團迫切需要籌集資金以償還其負債及為其未來營運提供資金。然而,集團最好將資源及人力集中於其核心業務,同時規避因進一步投資於要約人集團而產生的任何財務及管理風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account